ProFET: Serum Progesterone Levels on the Day of Frozen Embryo Transfer (FET) and Pregnancy Outcomes

Sponsor
CARE Fertility UK (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04170517
Collaborator
(none)
900
1
24
37.6

Study Details

Study Description

Brief Summary

Frozen embryo transfer (FET) cycles have become more common in recent years due to a push towards elective single embryo transfer (SET). While it is known that progesterone supplementation during the luteal phase improves clinical pregnancy rates, there is a paucity of prospective data on the impact of serum progesterone levels on pregnancy outcomes in FET cycles. This multicentre prospective cohort study aims to investigate the association between serum progesterone levels on the day of FET and pregnancy outcomes, and to determine a serum progesterone cut-off value above which clinical pregnancy and live birth are more likely to occur. Women undergoing ART-FET cycles at CARE Fertility clinics in the UK will be recruited and their serum progesterone measured on the day of frozen embryo transfer. Follow-up data will be stored in electronic patient records and analysed to determine whether a low serum progesterone level on the day of FET adversely affects ART outcomes.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Measurement of serum progesterone on the day of FET

Study Design

Study Type:
Observational
Anticipated Enrollment :
900 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Serum Progesterone Levels on the Day of Frozen Embryo Transfer (FET) and Pregnancy Outcomes
Actual Study Start Date :
Jan 2, 2020
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Outcome Measures

Primary Outcome Measures

  1. Live birth rate per participant [18 months]

    Birth of a live fetus at 24 or more weeks of gestational age

Secondary Outcome Measures

  1. Miscarriage rate per participant and per pregnancy [18 months]

    Any clinical pregnancy lost before week 12 of gestation per participant (number of events/number of participants, %)

  2. Implantation rates per participant [18 months]

    Number of gestational sacs seen in a 2D transvaginal ultrasound scan divided by the number of embryos transferred per patient (number of events/number of embryos transferred, %)

  3. Biochemical pregnancy rate per participant [18 months]

    Positive pregnancy test following embryo transfer per participant (number of events/number of participants, %)

  4. Clinical pregnancy rate per participant [18 months]

    Presence of at least one gestational sac on ultrasound (number of events/number of participants, %)

  5. Ectopic pregnancy rate per participant [18 months]

    number of events/number of participants, %

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • All women undergoing ART with FET.
Exclusion Criteria:
  • None. We aim to study the "every day" patient undergoing FET, and for this we intend to keep the population of the study as unselected as possible.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CARE Fertility Birmingham Birmingham United Kingdom

Sponsors and Collaborators

  • CARE Fertility UK

Investigators

  • Principal Investigator: Arri Coomarasamy, MBChB MD FRCOG, CARE Fertility UK

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CARE Fertility UK
ClinicalTrials.gov Identifier:
NCT04170517
Other Study ID Numbers:
  • ProFETStudy
First Posted:
Nov 20, 2019
Last Update Posted:
Oct 15, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 15, 2021